Pioglitazone

This classification denotes an anti-diabetic agent with the molecular formula C19H20N2O3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) X4OV71U42S, chemically known as 2,4-thiazolidinedione, 5-((4-(2-(5-ethyl-2-pyridinyl)ethoxy)phenyl)methyl)- but more generally known as pioglitazone, which bears US NIH Compound Identifier 4829. European Medicines Agency schedules Pioglitazone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09857MIG. The term PIOGLITAZONE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 3, No. 3, 1989, List 29) WHO schedules pioglitazone in its Anatomical Therapeutic Chemical (ATC) Classification. PIOGLITAZONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule pioglitazone under HS 29341000 and SITC 51579. As of Q4 2014, PIOGLITAZONE remains US FDA's Preferred Term for this commodity. Pioglitazone bears US NLM identifiers UMLS ID C0071097 and NCI Concept Code C71633. SMILES: S1C(CC2CCC(OCCC3NCC(CC)CC3)CC2)C(=O)NC1=O.